165 related articles for article (PubMed ID: 7720038)
1. The immunogenicity of MUC1 peptides and fusion protein.
Apostolopoulos V; Pietersz GA; Xing PX; Lees CJ; Michael M; Bishop J; McKenzie IF
Cancer Lett; 1995 Mar; 90(1):21-6. PubMed ID: 7720038
[TBL] [Abstract][Full Text] [Related]
2. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
Apostolopoulos V; Xing PX; McKenzie IF
Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
[TBL] [Abstract][Full Text] [Related]
3. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
4. Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein.
Apostolopoulos V; Xing PX; Trapani JA; McKenzie IF
Br J Cancer; 1993 Apr; 67(4):713-20. PubMed ID: 7682431
[TBL] [Abstract][Full Text] [Related]
5. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
6. Peptide epitopes in breast cancer mucins.
Xing PX; Apostolopoulos V; Trapani J; Prenzoska J; McKenzie IF
Adv Exp Med Biol; 1994; 353():9-16. PubMed ID: 7527180
[No Abstract] [Full Text] [Related]
7. Cellular Mucins: Targets for Immunotherapy.
Apostolopoulos V; McKenzie IFC
Crit Rev Immunol; 2017; 37(2-6):421-437. PubMed ID: 29773028
[TBL] [Abstract][Full Text] [Related]
8. CTL in mice immunized with human mucin 1 are MHC-restricted.
Apostolopoulos V; Loveland BE; Pietersz GA; McKenzie IF
J Immunol; 1995 Dec; 155(11):5089-94. PubMed ID: 7594517
[TBL] [Abstract][Full Text] [Related]
9. Induction of antibody responses to breast carcinoma associated mucins using synthetic peptide constructs as immunogens.
Denton G; Sekowski M; Price MR
Cancer Lett; 1993 Jul; 70(3):143-50. PubMed ID: 7689035
[TBL] [Abstract][Full Text] [Related]
10. Humanization of an anti-mucin antibody for breast and ovarian cancer therapy.
Baker TS; Bose CC; Caskey-Finney HM; King DJ; Lawson AD; Lyons A; Mountain A; Owens RJ; Rolfe MR; Sehdev M
Adv Exp Med Biol; 1994; 353():61-82. PubMed ID: 7985543
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan.
Apostolopoulos V; Pietersz GA; McKenzie IF
Vaccine; 1996 Jun; 14(9):930-8. PubMed ID: 8843637
[TBL] [Abstract][Full Text] [Related]
12. Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3.
Couto JR; Blank EW; Peterson JA; Kiwan R; Padlan EA; Ceriani RL
Adv Exp Med Biol; 1994; 353():55-9. PubMed ID: 7985542
[No Abstract] [Full Text] [Related]
13. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
Karanikas V; Hwang LA; Pearson J; Ong CS; Apostolopoulos V; Vaughan H; Xing PX; Jamieson G; Pietersz G; Tait B; Broadbent R; Thynne G; McKenzie IF
J Clin Invest; 1997 Dec; 100(11):2783-92. PubMed ID: 9389743
[TBL] [Abstract][Full Text] [Related]
14. Cellular mucins: targets for immunotherapy.
Apostolopoulos V; McKenzie IF
Crit Rev Immunol; 1994; 14(3-4):293-309. PubMed ID: 7538768
[TBL] [Abstract][Full Text] [Related]
15. Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.
Xing PX; Reynolds K; Pietersz GA; McKenzie IF
Immunology; 1991 Feb; 72(2):304-11. PubMed ID: 1707852
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
Ding L; Lalani EN; Reddish M; Koganty R; Wong T; Samuel J; Yacyshyn MB; Meikle A; Fung PY; Taylor-Papadimitriou J
Cancer Immunol Immunother; 1993; 36(1):9-17. PubMed ID: 8422670
[TBL] [Abstract][Full Text] [Related]
17. Phase-I study of synthetic muc1 peptides in breast-cancer.
Xing P; Michael M; Apostolopoulos V; Prenzoska J; Marshall C; Bishop J; McKenzie I
Int J Oncol; 1995 Jun; 6(6):1283-9. PubMed ID: 21556671
[TBL] [Abstract][Full Text] [Related]
18. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.
Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L
Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.
Brooks N; Hsu J; Esparon S; Pouniotis D; Pietersz GA
Molecules; 2018 Sep; 23(9):. PubMed ID: 30200528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
